ZVRA supply chain intelligence for Zevra Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LADX | LadRx Corporation | 90% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| LADX | LadRx Corporation | 90% | Reciprocal relationship from LADX graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from LADX graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from LADX g… |
| RELIEF | RELIEF | 90% | Pursuant to the Relief License Agreement, Zevra is obligated to pay royalties of 10% of U.S. net sales up to a maximum of $45.0 million, plus specified regulatory milestones, for total payments to Re… |
| AQST | Aquestive Therapeutics, Inc. | 85% | Under our March 2012 termination agreement with Aquestive Therapeutics, Aquestive has the right to receive a royalty amount equal to 10% of any value generated by AZSTARYS and any product candidates … |
| AQST | Aquestive Therapeutics, Inc. | 85% | Reciprocal relationship from AQST graph: Reciprocal relationship from ZVRA graph: Under our March 2012 termination agreement with Aquestive Therapeutics, Aquestive has the right to receive a royalty … |
| RELIEF-THERAPEUTICS-SA | RELIEF-THERAPEUTICS-SA | 80% | On August 30, 2023, Acer and Relief Therapeutics SA (“Relief”) entered into an exclusive license agreement |
| AYTU | Aytu BioPharma, Inc. | 72% | Reciprocal relationship from AYTU graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potent… |
| AYTU | Aytu BioPharma, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from ZVRA graph: vernment contracts or future orders… |
| MYGN | Myriad Genetics, Inc. | 72% | vernment contracts or future orders under existing contracts and civil and criminal liability, including False Claims Act liability, exclusion from participation in federal health care programs, and … |
| NVSEF | Novartis AG | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of ra… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVRA graph: . I n addition, we have solicited and applied for trademarks for the Zevra logo and several potential trade names an… |
| ORANY | ORANY | 72% | . I n addition, we have solicited and applied for trademarks for the Zevra logo and several potential trade names and logos for future product candidates. Third parties may oppose or attempt to cance… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potent… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| COMMAVE-THERAPEUTICS-SA | COMMAVE-THERAPEUTICS-SA | 92% | Commave has agreed to pay the Company a total of $50.0 million in cash, and the Company has agreed to sell, transfer, and assign to Commave all of the Company's right, title, and interest in and to c… |
| COMMAVE | COMMAVE | 90% | We entered into the AZSTARYS License Agreement with Commave pursuant to which we granted an exclusive, worldwide license to Commave to develop, manufacture and commercialize AZSTARYS |
| AYTU | Aytu BioPharma, Inc. | 72% | Reciprocal relationship from AYTU graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potent… |
| AYTU | Aytu BioPharma, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| LADX | LadRx Corporation | 72% | Reciprocal relationship from LADX graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potent… |
| LADX | LadRx Corporation | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| MYGN | Myriad Genetics, Inc. | 72% | that Corium will dedicate to the development, manufacturing or commercialization of AZSTARYS. Our ability to generate revenue under the AZSTARYS License Agreement will depend, in part, on Corium’s ab… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from ZVRA graph: that Corium will dedicate to the development, manufacturing or commercialization of AZSTARYS. Our ability to generate… |
| NVSEF | Novartis AG | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, poten… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from ORAN… |
| ORANY | ORANY | 72% | . I n addition, we have solicited and applied for trademarks for the Zevra logo and several potential trade names and logos for future product candidates. Third parties may oppose or attempt to cance… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ZVRA-DEBT-13794 | Warrants outstanding: 16650000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| ZVRA-DEBT-13795 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| ZVRA-DEBT | Debt stack $1.1M | 90% | Market cache reports total debt of $1.1M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ZVRA-OWNER-WOODLINE-PARTNERS-LP | Woodline Partners LP | 90% | 13F overlay lists Woodline Partners LP as top holder; 149 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| HLNCF | Haleon plc | 100.00 | 2 | |
| LQDA | Liquidia Corporation | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| COLL | Collegium Pharmaceutical, Inc. | 100.00 | 2 | |
| JBIO | Jade Biosciences, Inc. | 100.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ABT | Abbott Laboratories | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| HLN | Haleon plc | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| KLRS | Kalaris Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| OLMA | Olema Pharmaceuticals, Inc. | 100.00 | 2 |